SecBot SecBot
DEFA14A ·Filed Apr 20, 2026

PTCT

PTC THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago SEC0001104659-26-045533
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for any subsequent filings that might indicate changes in board dynamics or executive compensation trends, though this specific filing represents standard annual governance procedures.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$70.63
T+0 close · Apr 20, 2026 · via day close
Latest settled
+11.17%
T+60 · $78.52
Vs SPY
+4.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $70.63entry
  2. T+1 · 7mo ago +0.31%α −0.71% · $70.85
  3. T+5 · 7mo ago −0.52%α −1.61% · $70.26
  4. T+20 · 6mo ago −0.68%α −5.59% · $70.15
  5. T+60 · 4mo ago +11.17%α +4.27% · $78.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors, including Jessica Chutter who was recently appointed to the board. This filing is a definitive proxy statement soliciting shareholder votes on director elections, auditor ratification, and executive compensation. The filing follows a recent 8-K filing announcing Chutter's appointment and other board/executive changes, suggesting these materials are part of an ongoing governance process.

Key Financial Metrics

Vote
director election
Meeting
2026-06-02
Seats Contested
4

Key Facts

  • PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis
  • The proxy statement solicits votes on three proposals: election of directors, ratification of Ernst & Young as auditors, and approval of executive compensation
  • This filing follows a March 25, 2026 Form 8-K announcing Jessica Chutter's appointment to the board and other executive changes
  • The filing is routine corporate governance documentation for the annual shareholder meeting

Financial Impact

No direct financial impact - this is a routine governance filing

governanceboard composition

Risk Factors

  • Potential for shareholder activism if there are concerns about board composition or executive pay
  • Risk of low shareholder turnout for the vote

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-045533
Document: 0001104659-26-045533-index-headers.html0001104659-26-045533
Document: 0001104659-26-045533-index.html0001104659-26-045533
Document: 0001104659-26-045533.txt0001104659-26-045533

Track record

29 reports on PTCT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
  5. Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
  7. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
  8. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
  9. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
  10. Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026